Clinician Referrals for Non-opioid Pain Care Following Discontinuation of Long-term Opioid Therapy Differ Based on Reasons for Discontinuation
ABSTRACT
Background
Little is known about pain care offered to patients discontinued from long-term opioid therapy (LTOT) by their prescriber due to aberrant behaviors versus other reasons.
Objective
This study aimed to compare rates of non-opioid analgesic pharmacotherapy initiation and clinician referrals for non-pharmacologic pain treatment, complementary and integrative pain therapies, and specialty mental health and substance use disorder treatment between patients discontinued from opioid therapy due to aberrant behaviors versus other reasons.
Design
The design included retrospective manual electronic health record review and administrative data abstraction.
Participants
Patients were sampled from a national cohort of US Department of Veterans Affairs patients prescribed continuous opioid therapy in 2011 who subsequently discontinued opioid therapy in 2012. The study sample comprised 509 patients discontinued from LTOT by opioid-prescribing clinicians.
Main Measures
The primary independent variable was reason for discontinuation of LTOT (aberrant behaviors versus other reasons). Pain care dichotomous outcomes included clinician use of an opioid taper; initiating new non-opioid analgesic pharmacotherapy; and referrals for non-pharmacologic pain treatment, complementary and integrative pain therapies, and specialty mental health and substance use disorder treatment.
Key Results
We observed low rates of opioid taper (15% of patients), initiations of new or modifications of existing non-opioid analgesic pharmacotherapy (45% of patients), and clinician referrals for non-pharmacologic pain treatment (58% of patients) and complementary and integrative therapies (25% of patients). Patients discontinued due to aberrant behaviors, relative to patients discontinued for other reasons, were more likely to receive opioid tapers (adjusted OR = 5.60, 95% CI = 2.10–14.93), receive new non-opioid analgesic medications or dose changes to an existing non-opioid analgesic medications (adjusted OR = 2.61, 95% CI = 1.59–4.29), or be referred for specialty substance use disorder treatment (adjusted OR = 7.39, 95% CI = 3.76–14.53).
Conclusions
These findings highlight the variability in referral rates for different types of non-opioid pain treatments and challenges accessing specific types of pain care.
Notes
Acknowledgements
This work was supported by Locally Initiated Project Award no. QLP 59-048 (PI: Lovejoy) from the US Department of Veterans Affairs Substance Use Disorder Quality Enhancement Research Initiative. Dr. Lovejoy received additional support from Career Development Award IK2HX001516 from the US Department of Veterans Affairs Health Services Research and Development during preparation of this manuscript. We thank the VA Portland Health Care System and the US Department of Veterans Affairs Health Services Research and Development Center to Improve Veteran Involvement in Care (CIVIC; CIN 13-404, PI: Dobscha) at the VA Portland Health Care System for the provision of support and resources for this project.
Compliance with Ethical Standards
Disclaimer
The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs or U.S. Government.
Conflict of Interest
The authors declare that they have no conflicts of interest.
References
- 1.Pezalla EJ, Rosen D, Erensen JG, Haddox JD, Mayne TJ. Secular trends in opioid prescribing in the USA. J Pain Res. 2017;10:383–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Gellad WF, Good CB, Shulkin DJ. Addressing the opioid epidemic in the United States: lessons learned from the Department of Veterans Affairs. JAMA. 2017;177:611–2.Google Scholar
- 3.Lovejoy TI, Morasco BJ, Demidenko MI, Meath THA, Frank JW, Dobscha SK. Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders. Pain. 2017;158:526–34.CrossRefPubMedGoogle Scholar
- 4.Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315:1624–45.CrossRefPubMedGoogle Scholar
- 5.The Opioid Therapy for Chronic Pain Work Group. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. Washington, DC: U.S. Department of Veterans Affairs/U.S. Department of Defense; 2017.Google Scholar
- 6.Morasco BJ, Duckart JP, Dobscha SK. Adherence to clinical guidelines for opioid therapy for chronic pain in patients with substance use disorder. J Gen Intern Med. 2011;26:965–71.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Morasco BJ, Corson K, Turk DC, Dobscha SK. Association between substance use disorder status and pain-related function following 12 months of treatment in primary care patients with musculoskeletal pain. J Pain. 2011;12:352–9.CrossRefPubMedGoogle Scholar
- 8.Morrill R, Cromartie J, Hart G. Metropolitan, urban, and rural commuting areas: toward a better depiction of the United States settlement system. Urban Geogr. 1999;20:727–48.CrossRefGoogle Scholar
- 9.Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMedGoogle Scholar
- 10.Vanderlip ER, Sullivan MD, Edlund MJ, Martin BC, Jortney J, Austen M, Woilliams JS, Hudson T. National study of discontinuation of long-term opioid therapy among veterans. Pain. 2014;155:2673–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Mosher HJ, Krebs EE, Carrel M, Kaboli PJ, Weg MW, Lund BC. Trends in prevalent and incident opioid receipt: an observational study in Veterans Health Administration 2004-2012. J Gen Intern Med. 2015;30:597–604.CrossRefPubMedGoogle Scholar
- 12.Ilgen MA, Perron B, Czyk EK, McCammon RJ, Trafton J. The timing and onset of pain and substance use disorders. Am J Addict. 2010;19:409–15.CrossRefPubMedGoogle Scholar
- 13.Morasco BJ, Lovejoy TI, Ilgen MA. Management of chronic pain in patients with a comorbid substance use disorder. In Turk DC, Gatchel RJ, eds. Psychological Approaches to Pain Management: A Practitioner’s Handbook. 3rd Ed. New York, NY: The Guilford Press; 2018.Google Scholar
- 14.Stewart MO, Karlin BE, Murphy JL, Raffa SD, Miller SA, McKellar J, Kerns RD. National dissemination of cognitive-behavioral therapy for chronic pain in veterans: therapist and patient-level outcomes. Clin J Pain. 2015;31:722–729.CrossRefPubMedGoogle Scholar
- 15.Lin LA, Bohnert ASB, Kerns RD, Clay MA, Ganoczy D, Ilgen MA. Impact of the Opioid Safety Initiative on opioid-related prescribing in veterans. Pain. 2017;158:833–839.CrossRefPubMedGoogle Scholar
- 16.Teich J, Ali MM, Lynch S, Mutter R. Utilization of mental health services by veterans living in rural areas. J Rural Health. 2017;33:297–304.CrossRefPubMedGoogle Scholar
- 17.Chou R, Fanciullo GP, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–30.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.U.S. Department of Veterans Affairs/U.S. Department of Defense. VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. Washington, DC: Veterans Health Administration, 2010.Google Scholar
- 19.Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9:455–70.PubMedPubMedCentralGoogle Scholar
- 20.Krebs EE, Ramsey DC, Miloshoff JM, Bair MJ. Primary care monitoring of long-term opioid therapy among veterans with chronic pain. Pain Med. 2011;12:740–6.CrossRefPubMedGoogle Scholar